Inclusion Criteria:

- Female patients, >/= 18 years of age

- Histologically confirmed HER2-negative breast cancer

- Disease progression during or following first-line treatment with Avastin and
chemotherapy for locally recurrent or metastatic breast cancer

- Avastin treatment in first-line setting must have been a minimum of 4 cycles (15
mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy

- ECOG performance status 0-2

- At least 28 days since prior radiation therapy or surgery and recovery from treatment

Exclusion Criteria:

- Anti-angiogenic therapy or anti-vascular endothelial growth factors other than
Avastin for first-line treatment

- Active malignancy other than superficial basal cell and superficial squamous cell
carcinoma of the skin, or in situ carcinoma of the cervix or breast within the last 5
years

- Inadequate renal function

- Clinically relevant cardio-vascular disease

- Known CNS disease except for treated brain metastases

- Chronic daily treatment with high-dose aspirin (>325 mg/day) or clopidogrel (>75
mg/day)

- Pregnant or lactating women